AstraZeneca receives approval to market Durvalumab solution for infusion, used in the treatment of cancer for an additional indication (Source/Unsplash)
The company has received approval from the Central Drugs Standard Control Organization, Directorate General of Health Services, to import Durvalumab solution for infusion in strengths 120 mg/2.4 ml and 500 mg/10 ml (brand name Imfinzi) for an additional indication for sale and distribution, AstraZeneca Pharma said in a regulatory filing.
With this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or relapsed endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab monotherapy in endometrial cancer with a mismatch repair deficiency (dMMR).
The receipt of this approval paves the way for marketing of Durvalumab solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi) in India for the specified additional indication, subject to receipt of the associated regulatory approvals, it added.
(Only the headline and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)
First publication: February 10, 2026 | 2:40 PM IS
#AstraZeneca #receives #nod #Indian #regulator #launch #cancer #drug #Imfinzi